Reliable and dynamic partner in the Swiss healthcare market

Galenica can look back on a successful first six months of 2019. We have created added value for our stakeholders. This was achieved thanks to consistent implementation of our strategy, with dynamic further expansion of our pharmacy network, significant acquisitions and ongoing measures to increase efficiency within the Group as a whole.

Due to the good half-year results, the sales and earnings forecast for the current financial year 2019 as a whole has been raised slightly: we expect consolidated net sales for the Group as a whole to grow by between +1% and +3%, with sales growth of between +4% and +6% in the Health & Beauty segment and at the prior-year level up to +2% in the Services segment. The adjusted operating result (EBIT; excluding the effects of IAS 19 and IFRS 16) should increase by +5% to +7%. Due to the application of the new lease accounting standard IFRS 16, we expect an additional increase in EBIT of CHF 2 million to 3 million. Proposal of a dividend of at least the same level as the prior year (CHF 1.70 per share) to the 2020 Annual General Meeting is planned.

Bern, 6 August 2019